FDA Accepts Supplemental Application for ZOLADEX by TERSERA
The FDA has accepted a supplemental application for ZOLADEX (Goserelin Acetate) submitted by TERSERA.
Published: August 3, 2026
Updated: August 3, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Hormonal Therapy
Asset: TERSERA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
TERSERA
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's acceptance of TERSERA's supplemental application for ZOLADEX is significant as it may lead to enhanced market positioning in the oncology sector. This development warrants close monitoring to assess its impact on competitive dynamics and market share.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the progress of the review and any subsequent approvals or label changes.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.